Coats plus syndrome is an autosomal recessive multisystemic and pleiotropic disorder affecting the eyes, brain, bone, and gastrointestinal tract, usually caused by compound heterozygous variants of the conserved telomere maintenance component 1 gene (CTC1), involved in telomere homeostasis and replication. So far, most reported patients are compound heterozygous for a truncating mutation and a missense variant. The phenotype is believed to result from telomere dysfunction, with accumulation of DNA damage, cellular senescence, and stem cell depletion. Here, we report a 23-year-old female with prenatal and postnatal growth retardation, microcephaly, osteopenia, recurrent fractures, intracranial calcification, leukodystrophy, parenchymal brain cysts, bicuspid aortic valve, and primary ovarian failure. She carries a previously reported maternally inherited pathogenic variant in exon 5 (c.724_727del, p.(Lys242Leufs*41)) and a novel, paternally inherited splice site variant (c.1617+5G>T; p.(Lys480Asnfs*17)) in intron 9. CTC1 transcript analysis showed that the latter resulted in skipping of exon 9. A trace of transcripts was normally spliced resulting in the presence of a low level of wild-type CTC1 transcripts. We speculate that ovarian failure is caused by telomere shortening or chromosome cohesion failure in oocytes and granulosa cells, with early decrease in follicular reserve. This is the first patient carrying 2 truncating CTC1 variants and the first presenting primary ovarian failure.

1.
Briggs
TA
,
Abdel-Salam
GM
,
Balicki
M
,
Baxter
P
,
Bertini
E
,
Bishop
N
,
Cerebroretinal microangiopathy with calcifications and cysts (CRMCC)
.
Am J Med Genet A
.
2008
;
146a
(
2
):
182
90
. .
2.
Tolmie
JL
,
Browne
BH
,
McGettrick
PM
,
Stephenson
JB
.
A familial syndrome with coats’ reaction retinal angiomas, hair and nail defects and intracranial calcification
.
Eye
.
1988
;
2
(
Pt 3
):
297
303
. .
3.
Crow
YJ
,
McMenamin
J
,
Haenggeli
CA
,
Hadley
DM
,
Tirupathi
S
,
Treacy
EP
,
Coats’ plus: a progressive familial syndrome of bilateral Coats' disease, characteristic cerebral calcification, leukoencephalopathy, slow pre- and post-natal linear growth and defects of bone marrow and integument
.
Neuropediatrics
.
2004
;
35
(
1
):
10
9
. .
4.
Linnankivi
T
,
Valanne
L
,
Paetau
A
,
Alafuzoff
I
,
Hakumäki
JM
,
Kivelä
T
,
Cerebroretinal microangiopathy with calcifications and cysts
.
Neurology
.
2006
;
67
(
8
):
1437
43
. .
5.
Anderson
BH
,
Kasher
PR
,
Mayer
J
,
Szynkiewicz
M
,
Jenkinson
EM
,
Bhaskar
SS
,
Mutations in CTC1, encoding conserved telomere maintenance component 1, cause Coats plus
.
Nat Genet
.
2012
;
44
(
3
):
338
42
. .
6.
Polvi
A
,
Linnankivi
T
,
Kivelä
T
,
Herva
R
,
Keating
JP
,
Mäkitie
O
,
Mutations in CTC1, encoding the CTS telomere maintenance complex component 1, cause cerebroretinal microangiopathy with calcifications and cysts
.
Am J Hum Genet
.
2012
;
90
(
3
):
540
9
. .
7.
Stewart
JA
,
Wang
Y
,
Ackerson
SM
,
Schuck
PL
.
Emerging roles of CST in maintaining genome stability and human disease
.
Front Biosci
.
2018
;
23
:
1564
86
. .
8.
Amir
M
,
Khan
P
,
Queen
A
,
Dohare
R
,
Alajmi
MF
,
Hussain
A
,
Structural features of nucleoprotein CST/shelterin complex involved in the telomere maintenance and its association with disease mutations
.
Cells
.
2020
;
9
(
2
):
359
. .
9.
Wang
Y
,
Chai
W
.
Pathogenic CTC1 mutations cause global genome instabilities under replication stress
.
Nucleic Acids Res
.
2018
;
46
(
8
):
3981
92
. .
10.
Wang
F
,
Stewart
J
,
Price
CM
.
Human CST abundance determines recovery from diverse forms of DNA damage and replication stress
.
Cell Cycle
.
2014
;
13
(
22
):
3488
98
. .
11.
Feng
X
,
Hsu
SJ
,
Kasbek
C
,
Chaiken
M
,
Price
CM
.
CTC1-mediated C-strand fill-in is an essential step in telomere length maintenance
.
Nucleic Acids Res
.
2017
;
45
(
8
):
4281
93
. .
12.
Lim
CJ
,
Barbour
AT
,
Zaug
AJ
,
Goodrich
KJ
,
McKay
AE
,
Wuttke
DS
,
The structure of human CST reveals a decameric assembly bound to telomeric DNA
.
Science
.
2020
;
368
(
6495
):
1081
5
. .
13.
Gu
P
,
Chang
S
.
Functional characterization of human CTC1 mutations reveals novel mechanisms responsible for the pathogenesis of the telomere disease Coats plus
.
Aging Cell
.
2013
;
12
(
6
):
1100
9
. .
14.
Gu
P
,
Min
JN
,
Wang
Y
,
Huang
C
,
Peng
T
,
Chai
W
,
CTC1 deletion results in defective telomere replication, leading to catastrophic telomere loss and stem cell exhaustion
.
Embo J
.
2012
;
31
(
10
):
2309
21
. .
15.
Walne
AJ
,
Bhagat
T
,
Kirwan
M
,
Gitiaux
C
,
Desguerre
I
,
Leonard
N
,
Mutations in the telomere capping complex in bone marrow failure and related syndromes
.
Haematologica
.
2013
;
98
(
3
):
334
8
. .
16.
Sargolzaeiaval
F
,
Zhang
J
,
Schleit
J
,
Lessel
D
,
Kubisch
C
,
Precioso
DR
,
CTC1 mutations in a Brazilian family with progeroid features and recurrent bone fractures
.
Mol Genet Genomic Med
.
2018
;
6
(
6
):
1148
56
. .
17.
Keefe
DL
,
Marquard
K
,
Liu
L
.
The telomere theory of reproductive senescence in women
.
Curr Opin Obstet Gynecol
.
2006
;
18
(
3
):
280
5
. .
18.
Liu
L
,
Franco
S
,
Spyropoulos
B
,
Moens
PB
,
Blasco
MA
,
Keefe
DL
.
Irregular telomeres impair meiotic synapsis and recombination in mice
.
Proc Natl Acad Sci USA
.
2004
;
101
(
17
):
6496
501
. .
19.
Schuck
PL
,
Ball
LE
,
Stewart
JA
.
The DNA-binding protein CST associates with the cohesin complex and promotes chromosome cohesion
.
J Biol Chem
.
2021
;
297
(
3
):
101026
. .
20.
Caburet
S
,
Arboleda
VA
,
Llano
E
,
Overbeek
PA
,
Barbero
JL
,
Oka
K
,
Mutant cohesin in premature ovarian failure
.
N Engl J Med
.
2014
;
370
(
10
):
943
9
. .
21.
Wit
JM
,
Oostdijk
W
,
Losekoot
M
,
van Duyvenvoorde
HA
,
Ruivenkamp
CA
,
Kant
SG
.
Mechanisms in endocrinology: novel genetic causes of short stature
.
Eur J Endocrinol
.
2016
;
174
(
4
):
R145
73
. .
22.
de Bruin
C
,
Mericq
V
,
Andrew
SF
,
van Duyvenvoorde
HA
,
Verkaik
NS
,
Losekoot
M
,
An XRCC4 splice mutation associated with severe short stature, gonadal failure, and early-onset metabolic syndrome
.
J Clin Endocrinol Metab
.
2015
;
100
(
5
):
E789
98
. .
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.